Connect your AI

Immunome IMNM Available For Sale Debt Securities Gross Unrealized Gain

Available For Sale Debt Securities Gross Unrealized Gain at other companies

HTF

Heartflow, Inc. Common StockHTFL

$42.25K—

CleanSparkCLSK

-$2.76M-3,103%

Cal-Maine FoodsCALM

$2.96M+592%

HTF

Heartflow, Inc. Common StockHTFL

$3.75K—

Grand Canyon EducationLOPE

$151K+36.0%

State StreetSTT

$174M-14.7%

Other financials

Income statement

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

Market cap$2.24B+323%

Enterprise value$1.66B+470%

P/S557.1×+509×

Profitability

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain.

The official record: Immunome’s 10-K, filed March 28, 2024, on SEC EDGAR. View the filing →

Ask your AI about Immunome's available for sale debt securities gross unrealized gain.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Immunome's available for sale debt securities gross unrealized gain?: Immunome (IMNM) reported available for sale debt securities gross unrealized gain of $5.5K in Q4 2023.